Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stefano Coppola-Fasick

Nephrology Guaynabo, PR Medical Doctor

NPI 1831585918 CMS profile 5704811

9429 Martinez Nadal Km 3.4, 2 Lote # J20, Guaynabo, PR 00969

Open in the dashboard

General payments

$7,514

93 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stefano Coppola-Fasick of Guaynabo, PR is reported in the CMS Open Payments database as having received $7,514 across 93 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $407 8
2024 General $320 5
2023 General $231 3
2022 General $51 3
2021 General $3,070 30
2020 General $2,188 13
2019 General $1,246 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stefano Coppola-Fasick
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Stefano Coppola-Fasick were reported at $407. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Stefano Coppola-Fasick Nephrology median Middle half National median
2019 $1,246 $236 $90–$588 $163
2020 $2,188 $135 $46–$364 $114
2021 $3,070 $202 $67–$551 $132
2022 $51 $242 $77–$695 $149
2023 $231 $254 $84–$766 $160
2024 $320 $300 $99–$852 $164
2025 $407 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Fresenius USA Marketing, Inc. $2,586 14 payments
  2. Bard Peripheral Vascular, Inc. $2,329 20 payments
  3. AstraZeneca Pharmaceuticals LP $536 19 payments
  4. Otsuka America Pharmaceutical, Inc. $330 11 payments
  5. Mallinckrodt Hospital Products Inc. $312 3 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $287 4 payments
  7. Becton, Dickinson and Company $246 8 payments
  8. GlaxoSmithKline, LLC. $237 2 payments
  9. Calliditas Therapeutics US Inc. $182 2 payments
  10. Mallinckrodt Enterprises LLC $115 2 payments
  11. Other $354 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,359 77 payments
  2. Travel and Lodging $2,924 10 payments
  3. Education $231 6 payments
Products named General payments · program years 2019–2025
  1. COVERA $950 4 payments
  2. CONQUEST $665 5 payments
  3. LOKELMA $523 18 payments
  4. JYNARQUE $318 9 payments
  5. ACTHAR Immunology $312 3 payments
  6. Kerendia $287 4 payments
  7. TARPEYO $182 2 payments
  8. ACTHAR Autoimmune And Rare Disease $115 2 payments
  9. BENLYSTA $112 1 payment
  10. GlidePath $95 1 payment
  11. Other $458 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

93 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record